PMID- 22233024
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20141120
IS  - 0342-9601 (Print)
IS  - 0342-9601 (Linking)
VI  - 34
IP  - 12
DP  - 2011 Dec
TI  - [Therapy of gastroesophageal reflux disease (GERD)].
PG  - 446-54; quiz 455-6
AB  - Gastroesophageal reflux disease (GERD) comprises all symptoms and clinical 
      consequences in the context of reflux of stomach contents into the esophagus. The 
      symptoms reported by patients include heartburn, regurgitation and sour taste in 
      the mouth. In some cases atypical reflux associated symptoms such as asthma, 
      laryngitis or recurrent pneumonias are reported. Pathophysiologically an 
      incompetence of the lower esophageal sphincter and a disturbed clearance of the 
      esophagus are the underlying mechanisms. Current treatment recommendations 
      include a change of lifestyle and a drug treatment with proton pump inhibitors 
      (PPI) being widely used. In patients with persistent symptoms other diagnoses 
      like functional dyspepsia should be considered especially when additional 
      symptoms like epigastric pain, postprandial fullness and nausea are present. This 
      review summarizes the current understanding of the pathophysiology, the diagnosis 
      and the treatment of GERD and gives an outlook on therapies currently developed 
      for the treatment of reflux disease. A promising new drug, presently classified 
      as being a reflux inhibitor, is lesogaberan. Lesogaberan is presently studied in 
      phase II clinical trials.
FAU - Storr, Martin
AU  - Storr M
AD  - Medizinische Klinik II der Ludwig-Maximilians-Universitat Munchen, Klinikum 
      Grosshadern, Marchioninistrasse 15, 81377 Munchen. grdoc@gmx.com
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aktuelle und zukunftige Therapien der gastroosophagealen Refluxerkrankung.
PL  - Germany
TA  - Med Monatsschr Pharm
JT  - Medizinische Monatsschrift fur Pharmazeuten
JID - 7802665
RN  - 0 (Antacids)
RN  - 0 (GABA Antagonists)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Phosphinic Acids)
RN  - 0 (Propylamines)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Receptors, GABA-A)
RN  - 4D6Q6HGC7Z (lesogaberan)
SB  - IM
MH  - Antacids/therapeutic use
MH  - Drug Resistance
MH  - GABA Antagonists/therapeutic use
MH  - Gastroesophageal Reflux/complications/diagnosis/drug 
      therapy/epidemiology/*therapy
MH  - Histamine H2 Antagonists/therapeutic use
MH  - Humans
MH  - Phosphinic Acids/therapeutic use
MH  - Propylamines/therapeutic use
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Receptors, GABA-A/drug effects
EDAT- 2012/01/12 06:00
MHDA- 2012/02/01 06:00
CRDT- 2012/01/12 06:00
PHST- 2012/01/12 06:00 [entrez]
PHST- 2012/01/12 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
PST - ppublish
SO  - Med Monatsschr Pharm. 2011 Dec;34(12):446-54; quiz 455-6.